Roche Inks Another AAV Capsid Platform Technology Deal, With Avista Therapeutics
Deal Snapshot: Roche and University of Pittsburgh spinout Avista Therapeutics signed the pact to enable the Swiss drug maker to develop gene therapies for retinal diseases using Avista’s platform tech.
You may also be interested in...
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
The California-based biotech is reducing its workforce to help finance a Phase II study of Ixo-vec, its eye gene therapy which has been blighted by safety concerns.